Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant.

Berenguer J, Jarrín I, Pérez-Latorre L, Hontañón V, Vivancos MJ, Navarro J, Téllez MJ, Guardiola JM, Iribarren JA, Rivero-Juárez A, Márquez M, Artero A, Morano L, Santos I, Moreno J, Fariñas MC, Galindo MJ, Hernando MA, Montero M, Cifuentes C, Domingo P, Sanz J, Domíngez L, Ferrero OL, De la Fuente B, Rodríguez C, Reus S, Hernández-Quero J, Gaspar G, Pérez-Martínez L, García C, Force L, Veloso S, Losa JE, Vilaró J, Bernal E, Arponen S, Ortí AJ, Chocarro Á, Teira R, Alonso G, Silvariño R, Vegas A, Geijo P, Bisbe J, Esteban H, González-García J; GeSIDA 8514 Study Group.

Open Forum Infect Dis. 2018 Jan 12;5(1):ofx258. doi: 10.1093/ofid/ofx258. eCollection 2018 Jan.

2.

Hepatitis C testing and re-testing among people attending sexual health services in Australia, and hepatitis C incidence among people with human immunodeficiency virus: analysis of national sentinel surveillance data.

Boettiger DC, Law MG, Dore GJ, Guy R, Callander D, Donovan B, O'Connor CC, Fairley CK, Hellard M, Matthews G.

BMC Infect Dis. 2017 Dec 1;17(1):740. doi: 10.1186/s12879-017-2848-0.

3.

Detection and analysis of hepatitis C virus in HIV-infected patients in the Guangxi province of China.

Wu SZ, Wei JL, Xu B, Wei PH, Yang Y, Qin B, Xie ZC.

Exp Ther Med. 2017 Mar;13(3):917-923. doi: 10.3892/etm.2017.4067. Epub 2017 Jan 20.

4.

Treatment optimization for HIV/HCV co-infected patients.

Scott JA, Chew KW.

Ther Adv Infect Dis. 2017 Jan;4(1):18-36. doi: 10.1177/2049936116681279. Epub 2016 Dec 9. Review.

5.

The association between age of onset of opioid use and comorbidity among opioid dependent patients receiving methadone maintenance therapy.

Naji L, Dennis BB, Bawor M, Varenbut M, Daiter J, Plater C, Pare G, Marsh DC, Worster A, Desai D, MacKillop J, Thabane L, Samaan Z.

Addict Sci Clin Pract. 2017 Mar 28;12(1):9. doi: 10.1186/s13722-017-0074-0.

6.

Inactivation of HCV and HIV by microwave: a novel approach for prevention of virus transmission among people who inject drugs.

Siddharta A, Pfaender S, Malassa A, Doerrbecker J, Anggakusuma, Engelmann M, Nugraha B, Steinmann J, Todt D, Vondran FW, Mateu-Gelabert P, Goffinet C, Steinmann E.

Sci Rep. 2016 Nov 18;6:36619. doi: 10.1038/srep36619.

7.

Statin drugs decrease progression to cirrhosis in HIV/hepatitis C virus coinfected individuals.

Oliver NT, Hartman CM, Kramer JR, Chiao EY.

AIDS. 2016 Oct 23;30(16):2469-2476.

8.

Hepatitis C Screening in People With Human Immunodeficiency Virus: Lessons Learned From Syphilis Screening.

Wurcel AG, Chen DD, Fitzpatrick RE, Grasberger PE, Kirshner CH, Anderson JE, Chui KK, Knox TA.

Open Forum Infect Dis. 2016 Feb 12;3(1):ofv215. doi: 10.1093/ofid/ofv215. eCollection 2016 Jan.

9.

Role of Marine Natural Products in the Genesis of Antiviral Agents.

Gogineni V, Schinazi RF, Hamann MT.

Chem Rev. 2015 Sep 23;115(18):9655-706. doi: 10.1021/cr4006318. Epub 2015 Aug 28. Review. No abstract available.

10.

The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UK.

Inshaw J, Leen C, Fisher M, Gilson R, Hawkins D, Collins S, Fox J, McLean K, Fidler S, Phillips A, Lattimore S, Babiker A, Porter K; UK HIV Seroconverters Cohort.

PLoS One. 2015 Jul 30;10(7):e0132772. doi: 10.1371/journal.pone.0132772. eCollection 2015.

11.

Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection.

Matthews L, Kleiner DE, Chairez C, McManus M, Nettles MJ, Zemanick K, Morse CG, Benator D, Kovacs JA, Hadigan C.

AIDS Res Hum Retroviruses. 2015 Oct;31(10):961-6. doi: 10.1089/AID.2015.0093. Epub 2015 Aug 24.

12.

The Ryan White HIV/AIDS Program in the Age of Health Care Reform.

Cahill SR, Mayer KH, Boswell SL.

Am J Public Health. 2015 Jun;105(6):1078-85. doi: 10.2105/AJPH.2014.302442. Epub 2015 Apr 16.

13.

Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection.

Truong WR, Schafer JJ, Short WR.

P T. 2015 Jan;40(1):44-55.

14.

Differential regulation of cytotoxicity pathway discriminating between HIV, HCV mono- and co-infection identified by transcriptome profiling of PBMCs.

Wu JQ, Saksena MM, Soriano V, Vispo E, Saksena NK.

Virol J. 2015 Jan 27;12:4. doi: 10.1186/s12985-014-0236-6.

15.

The effect of HIV viral control on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV coinfection.

Kramer JR, Kowalkowski MA, Duan Z, Chiao EY.

J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):456-62. doi: 10.1097/QAI.0000000000000494.

16.

Characteristics of HCV co-infection among HIV infected individuals from an area with high risk of blood-borne infections in central China.

Zhang T, Tully DC, Zhou S, He N.

PLoS One. 2014 Apr 7;9(4):e94219. doi: 10.1371/journal.pone.0094219. eCollection 2014.

17.

Hepatitis C Virus and HIV Type 1 Co-Infection.

Gupta P.

Infect Dis Rep. 2013 Jun 6;5(Suppl 1):e7. doi: 10.4081/idr.2013.s1.e7. eCollection 2013 Jun 6. Review.

18.

The spectrum of undiagnosed hepatitis C virus infection in a US HIV clinic.

Taylor LE, Foont JA, DeLong AK, Wurcel A, Linas BP, Chapman S, Maynard MA, Cu-Uvin S, Mayer KH.

AIDS Patient Care STDS. 2014 Jan;28(1):4-9. doi: 10.1089/apc.2013.0130.

19.

Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014.

Chastain CA, Naggie S.

Curr HIV/AIDS Rep. 2013 Dec;10(4):408-19. doi: 10.1007/s11904-013-0182-8. Review.

20.

Design and Development of a Multiplex Real-Time PCR Assay for Detection of HIV-1 and HCV Using Molecular Beacons.

Paryan M, Mohammadi-Yeganeh S, Mirab Samiee S, Rezvan H.

Indian J Microbiol. 2012 Sep;52(3):456-63. doi: 10.1007/s12088-012-0271-1. Epub 2012 May 11.

Supplemental Content

Support Center